Molecular Diagnosis & Therapy

, Volume 18, Issue 4, pp 389–402 | Cite as

Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential

  • Giuseppe Galletti
  • Luigi Portella
  • Scott T. Tagawa
  • Brian J. Kirby
  • Paraskevi Giannakakou
  • David M. Nanus
Review Article

Abstract

Circulating tumor cells (CTCs) have emerged as a viable solution to the lack of tumor tissue availability for patients with a variety of solid tumors, including prostate cancer. Different approaches have been used to capture this tumor cell population and several of these techniques have been used to assess the potential role of CTCs as a biological marker to predict treatment efficacy and clinical outcome. CTCs are now considered a strong tool to understand the molecular characteristics of prostate cancer, and to be used and analyzed as a ‘liquid biopsy’ in the attempt to grasp the biological portrait of the disease in the individual patient.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol. 2012;30(6):644–6.PubMedCrossRefGoogle Scholar
  3. 3.
    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Fenner A. Prostate cancer: abiraterone increases overall survival in men with castration-resistant prostate cancer. Nat Rev Urol. 2011;8(7):351.PubMedCrossRefGoogle Scholar
  5. 5.
    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Hoffman-Censits J, Kelly WK. Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(6):1335–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.PubMedCrossRefGoogle Scholar
  9. 9.
    de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–54.PubMedCrossRefGoogle Scholar
  10. 10.
    Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25(25):3965–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Fleming MT, Morris MJ, Heller G, Scher HI. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol. 2006;3(12):658–67.PubMedCrossRefGoogle Scholar
  12. 12.
    Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN Jr, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98(8):516–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: “RECIST”ing a step backwards. Clin Cancer Res. 2005;11(14):5223–32.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–4.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Fizazi K, Morat L, Chauveinc L, Prapotnich D, De Crevoisier R, Escudier B, et al. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol. 2007;18(3):518–21.PubMedCrossRefGoogle Scholar
  17. 17.
    Harouaka R, Kang Z, Zheng SY, Cao L. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther. 2014;141:209–21.PubMedCrossRefGoogle Scholar
  18. 18.
    Xu T, Lu B, Tai YC, Goldkorn A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microfilter. Cancer Res. 2010;70(16):6420–6.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Zheng S, Lin HK, Lu B, Williams A, Datar R, Cote RJ, et al. 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices. 2011;13(1):203–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Harouaka RA, Nisic M, Zheng SY. Circulating tumor cell enrichment based on physical properties. J Lab Autom. 2013;18(6):455–68.PubMedCrossRefGoogle Scholar
  21. 21.
    Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, et al. A direct comparison of Cell Search and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer. 2011;105(6):847–53.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, et al. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol. 2012;9(1):016002.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, et al. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012;9(1):016003.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, et al. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012;9(1):016001.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P, et al. Cytomorphology of circulating colorectal tumor cells: a small case series. J Oncol. 2010;2010:861341.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Dittamore R, Louw J, Krupa R, Anand A, Danila DC, Arslan Z, et al. Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC). Genitourinary cancers symposium; 2014.Google Scholar
  27. 27.
    Ferraldeschi R, Krupa R, Louw J, Tucker E, Bales N, Marrinucci D, et al. Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics. Genitourinary cancers symposium; 2014.Google Scholar
  28. 28.
    Han SI, Joo YD, Han KH. An electrorotation technique for measuring the dielectric properties of cells with simultaneous use of negative quadrupolar dielectrophoresis and electrorotation. Analyst. 2013;138(5):1529–37.PubMedCrossRefGoogle Scholar
  29. 29.
    Pratt ED, Huang C, Hawkins BG, Gleghorn JP, Kirby BJ. Rare cell capture in microfluidic devices. Chem Eng Sci. 2011;66(7):1508–22.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Gascoyne PR, Noshari J, Anderson TJ, Becker FF. Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis. 2009;30(8):1388–98.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.
    Huang C, Liu H, Bander NH, Kirby BJ. Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system. Biomed Microdevices. 2013;15(6):941–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Huang SB, Wu MH, Lin YH, Hsieh CH, Yang CL, Lin HC, et al. High-purity and label-free isolation of circulating tumor cells (CTCs) in a microfluidic platform by using optically-induced-dielectrophoretic (ODEP) force. Lab Chip. 2013;13(7):1371–83.PubMedCrossRefGoogle Scholar
  33. 33.
    He W, Kularatne SA, Kalli KR, Prendergast FG, Amato RJ, Klee GG, et al. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer. 2008;123(8):1968–73.PubMedCentralPubMedCrossRefGoogle Scholar
  34. 34.
    Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13(23):7053–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, et al. Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012;2(11):995–1003.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10(3):233–9.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Goodman OB Jr, Symanowski JT, Loudyi A, Fink LM, Ward DC, Vogelzang NJ. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer. Clin Genitourin Cancer. 2011;9(1):31–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897–904.PubMedCrossRefGoogle Scholar
  39. 39.
    Cann GM, Gulzar ZG, Cooper S, Li R, Luo S, Tat M, et al. mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. PLoS ONE. 2012;7(11):e49144.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450(7173):1235–9.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci USA. 2010;107(43):18392–7.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013;5(179):179ra47.PubMedCentralPubMedCrossRefGoogle Scholar
  43. 43.
    Galletti G, Sung MS, Vahdat LT, Shah MA, Santana SM, Altavilla G, et al. Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip. 2014;14(1):147–56.PubMedCrossRefGoogle Scholar
  44. 44.
    Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, et al. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip. 2010;10(1):27–9.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Kirby BJ, Jodari M, Loftus MS, Gakhar G, Pratt ED, Chanel-Vos C, et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS ONE. 2012;7(4):e35976.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    Antonarakis ES, Giannakakou P, Kirby BJ, Nicacio LV, Eisenberger MA, Nanus D, et al. TAXYNERGY (NCT01718353): a randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC). ASCO annual meeting; 2013.Google Scholar
  47. 47.
    Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998;95(8):4589–94.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Wu LY, Liu T, Grimm AL, Davis WC, Berkman CE. Flow cytometric detection of prostate tumor cells using chemoaffinity labels. Prostate. 2011;71(1):52–61.PubMedCrossRefGoogle Scholar
  49. 49.
    Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011;17(12):3903–12.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Gakhar G, Navarro VN, Jurish M, Lee GY, Tagawa ST, Akhtar NH, et al. Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PLoS ONE. 2013;8(12):e85143.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Hughes AD, Mattison J, Western LT, Powderly JD, Greene BT, King MR. Microtube device for selectin-mediated capture of viable circulating tumor cells from blood. Clin Chem. 2012;58(5):846–53.PubMedCrossRefGoogle Scholar
  52. 52.
    Alix-Panabieres C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods. 2005;299(1–2):177–88.PubMedCrossRefGoogle Scholar
  53. 53.
    Alix-Panabieres C, Vendrell JP, Slijper M, Pelle O, Barbotte E, Mercier G, et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res. 2009;11(3):R39.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Alix-Panabieres C, Rebillard X, Brouillet JP, Barbotte E, Iborra F, Segui B, et al. Detection of circulating prostate-specific antigen-secreting cells in prostate cancer patients. Clin Chem. 2005;51(8):1538–41.PubMedCrossRefGoogle Scholar
  55. 55.
    Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard X, Riethdorf S, Muller V, et al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem. 2007;53(3):537–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529–34.PubMedCrossRefGoogle Scholar
  57. 57.
    Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA. 1994;272(10):773–80.PubMedCrossRefGoogle Scholar
  58. 58.
    Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151(5):1283–90.PubMedGoogle Scholar
  59. 59.
    Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–9.PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Cooperberg MR, Carroll PR. Prostate-cancer screening. N Engl J Med. 2009;361(2):203 author reply 4–5.PubMedGoogle Scholar
  61. 61.
    Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302(15):1685–92.PubMedCrossRefGoogle Scholar
  63. 63.
    Thalgott M, Rack B, Maurer T, Souvatzoglou M, Eiber M, Kress V, et al. Detection of circulating tumor cells in different stages of prostate cancer. J Cancer Res Clin Oncol. 2013;139(5):755–63.PubMedCrossRefGoogle Scholar
  64. 64.
    Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010;2(25):25ra3.CrossRefGoogle Scholar
  65. 65.
    Murray NP, Reyes E, Badinez L, Orellana N, Fuentealba C, Olivares R, et al. Circulating prostate cells found in men with benign prostate disease are P504S negative: clinical implications. J Oncol. 2013;2013:165014.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Beach R, Gown AM, De Peralta-Venturina MN, Folpe AL, Yaziji H, Salles PG, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol. 2002;26(12):1588–96.PubMedCrossRefGoogle Scholar
  67. 67.
    Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005;65(4):713–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Kollermann J, Weikert S, Schostak M, Kempkensteffen C, Kleinschmidt K, Rau T, et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol. 2008;26(30):4928–33.PubMedCrossRefGoogle Scholar
  69. 69.
    Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213–21.PubMedCrossRefGoogle Scholar
  70. 70.
    Sawabata N, Okumura M, Utsumi T, Inoue M, Shiono H, Minami M, et al. Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg. 2007;55(5):189–92.PubMedCrossRefGoogle Scholar
  71. 71.
    de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Chen BT, Loberg RD, Neeley CK, O’Hara SM, Gross S, Doyle G, et al. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology. 2005;65(3):616–21.PubMedCrossRefGoogle Scholar
  73. 73.
    Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol. 2009;20(1):27–33.PubMedCrossRefGoogle Scholar
  74. 74.
    Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, et al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol. 2008;179(6):2187–91 discussion 91.PubMedCrossRefGoogle Scholar
  75. 75.
    FDA Clearance Document for Veridex LLC.Cell-Search(TM) Circulating Tumor Cell Kit. Premarket notification—expanded indications for use—metastatic prostate cancer; 2008. http://www.accessdata.fda.gov/cdrh_docs/pdf7/K073338.pdf. Cited 21 Nov 2013.
  76. 76.
    Vaishampayan UN, Fontana J, Heilbrun LK, Smith D, Heath E, Dickow B, et al. Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. Urol Oncol. 2014;32:31.PubMedCrossRefGoogle Scholar
  77. 77.
    Armstrong AJ, Shen T, Halabi S, Kemeny G, Bitting RL, Kartcheske P, et al. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Clin Genitourin Cancer. 2013;11:397–406.PubMedCrossRefGoogle Scholar
  78. 78.
    Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013;19(11):3088–94.PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Shamash J, Jacob J, Agrawal S, Powles T, Mutsvangwa K, Wilson P, et al. Whole blood stem cell reinfusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study. Clin Cancer Res. 2012;18(8):2352–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, et al. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol. 2014.Google Scholar
  81. 81.
    Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46.PubMedCentralPubMedCrossRefGoogle Scholar
  82. 82.
    Anand A, Scher HI, Beer TM, Higano CS, Danila DC, Taplin M, et al. Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naive patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100. ASCO annual meeting; 2010.Google Scholar
  83. 83.
    Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010;28(9):1489–95.PubMedCentralPubMedCrossRefGoogle Scholar
  84. 84.
    Scher HI, Heller G, Molina A. Evaluation of a composite biomarker panel including circulating tumor cell enumeration as a surrogate for survival in metastatic castration resistant prostate cancer. European Cancer Congress; 2013.Google Scholar
  85. 85.
    Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011;9(8):997–1007.PubMedCentralPubMedCrossRefGoogle Scholar
  86. 86.
    Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate. 2013;73(8):813–26.PubMedCrossRefGoogle Scholar
  87. 87.
    Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res. 2007;13(7):2023–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res. 2009;15(6):2091–7.PubMedCentralPubMedCrossRefGoogle Scholar
  89. 89.
    Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A’Hern R, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009;69(7):2912–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Tagawa et al. TAXYNERGY (NCT01718353): A randomized phase II trial examining an early switch from first-line docetaxel to cabazitaxel, or cabazitaxel to docetaxel, in men with metastatic castration-resistant prostate cancer (mCRPC). ASCO Annual Meeting. J Clin. Oncol. 2013;31(15 Suppl), abstract no TPS5100Google Scholar
  91. 91.
    Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010;70(20):7992–8002.PubMedCentralPubMedCrossRefGoogle Scholar
  92. 92.
    Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 2011;71(18):6019–29.PubMedCentralPubMedCrossRefGoogle Scholar
  93. 93.
    Thadani-Mulero M, Nanus DM, Giannakakou P. Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res. 2012;72(18):4611–5.PubMedCentralPubMedCrossRefGoogle Scholar
  94. 94.
    Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014.Google Scholar
  95. 95.
    Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644–8.PubMedCrossRefGoogle Scholar
  96. 96.
    Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008;8(7):497–511.PubMedCentralPubMedCrossRefGoogle Scholar
  97. 97.
    Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31(6):882–8.PubMedCrossRefGoogle Scholar
  98. 98.
    Cai C, Wang H, Xu Y, Chen S, Balk SP. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer. Cancer Res. 2009;69(15):6027–32.PubMedCentralPubMedCrossRefGoogle Scholar
  99. 99.
    Galletti G, Beltran H, Matov A, Fontugne J, Mosquera JM, Fazli L, et al. ERG induces taxane resistance in castration-resistant prostate cancer. AACR annual meeting 2013; 2013.Google Scholar
  100. 100.
    Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM, et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol. 2012;30(36):e386–9.PubMedCrossRefGoogle Scholar
  101. 101.
    Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033–41.PubMedCrossRefGoogle Scholar
  102. 102.
    Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10(21):7121–6.PubMedCrossRefGoogle Scholar
  103. 103.
    Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, et al. Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012;72(23):6142–52.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  • Giuseppe Galletti
    • 1
  • Luigi Portella
    • 1
  • Scott T. Tagawa
    • 1
  • Brian J. Kirby
    • 1
    • 2
  • Paraskevi Giannakakou
    • 1
  • David M. Nanus
    • 1
    • 3
  1. 1.Division of Hematology and Medical Oncology and the Weill Cornell Cancer CenterWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Sibley School of Mechanical and Aerospace Engineering, Cornell UniversityIthacaUSA
  3. 3.Division of Hematology and Medical Oncology and the Weill Cornell Cancer CenterWeill Cornell Medical CollegeNew YorkUSA

Personalised recommendations